Answers to the CME Quiz for "Prediction and Prevention of Recurrent Preeclampsia” by John R. Barton, MD, and Baha M. Sibai, MD (Obstet Gynecol 2008;112:359-72)

1. In certain women with a prior pregnancy complicated by preeclampsia (second trimester), the recurrence rate can be as high as:

D. 65%

2. By the definition of preeclampsia, which of the following findings would be classified as proteinuria?

B. 40 mg/dL in two samples 12 hours apart

3. Which of the following preconceptional or preexisting risk factors for preeclampsia conveys the greatest reported risk?

C. Chronic hypertension

4. For diabetic women, the risk of preeclampsia is most dependent upon their:

A. White’s classification

5. Which of the following factors is associated with a reduced rate of preeclampsia?

E. Smoking

6. The use of uterine artery Doppler measurements to predict preeclampsia is associated with a positive predictive value of no greater than:

A. 40%

7. For selected patients, which of the following have been associated with a reduction in the risk of recurrent preeclampsia?

C. Low-dose aspirin therapy

8. For a patient with preeclampsia during a previous pregnancy, the authors recommend beginning weekly prenatal visits at about:

D. 32 weeks

ACCME Accreditation: The American College of Obstetricians and Gynecologists (ACOG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. (Continuing medical education credit for "Prediction and Prevention of Recurrent Preeclampsia” will be available through August 2011.)

AMA PRA Category 1 Credit^TM and ACOG Cognate Credit: The American College of Obstetricians and Gynecologists (ACOG) designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits^TM or up to a maximum of 2 Category 1 ACOG cognate credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Statement: Current guidelines state that continuing medical education (CME) providers must ensure that CME activities are free from the control of any commercial interest. All authors, reviewers, and contributors have disclosed to ACOG all relevant financial relationships with any commercial interests. The authors have made the following disclosures: Dr. Barton is involved in investigating the potential use of biochemical markers to predict preeclampsia for Beckman Coulter, Inc. (Fullerton, CA). Dr. Sibai acts as a consultant to Beckman Coulter, Inc., and Ortho Clinical Diagnostics, Inc. (Rochester, NY), regarding the potential use of biochemical markers to predict preeclampsia. Any conflicts have been resolved through group and outside review of all content.

Return to the Obstetrics & Gynecology web site.